Impact of mycophenolate mofetil on lung function in chronic hypersensitivity pneumonitis and connective tissue disease related-ILD Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020
Use of mycophenolate mofetil for the treatment of hypersensitivity pneumonitis> Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020
Safety and effectiveness of mycophenolate mofetil in interstitial lung diseases Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021
Results of switch from mycophenolate mofetil to azathioprin after lung transplantation Source: Eur Respir J 2004; 24: Suppl. 48, 178s Year: 2004
Churg-Strauss syndrome treated with mycophenolate mofetil Source: Eur Respir J 2002; 20: Suppl. 38, 65s Year: 2002
Mycophenolate mofetil: an effective corticosteroid-sparing drug in steroid-dependent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005
Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis Source: Eur Respir J, 57 (3) 2002872; 10.1183/13993003.02872-2020 Year: 2021
Can mycophenolate mofetil 15 mg/kg/day attenuate experimental pulmonary fibrosis in rats? Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009
Mycophenolate mofetil (MMF) rescue therapy in lung transplantation: results and pharmacokinetics Source: Eur Respir J 2002; 20: Suppl. 38, 348s Year: 2002
A case series on the use of steroids and mycophenolate mofetil in idiopathic and heritable pulmonary veno-occlusive disease: is there a role for immunosuppression? Source: Eur Respir J, 57 (6) 2004354; 10.1183/13993003.04354-2020 Year: 2021
Pneumocystis jiroveci Pneumonia prophylaxis in patients treated with mycophenolate mofetil for interstitial lung disease Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021
Azathioprine and low-dose prednisone in chronic pulmonary sarcoidosis Source: Eur Respir J 2005; 26: Suppl. 49, 268s Year: 2005
Mycophenolate mofetil reduces alveolar inflammation and acute rejection and improves overall outcome after lung transplantation Source: Eur Respir J 2006; 28: Suppl. 50, 724s Year: 2006
Pulmonary alveolar proteinosis due to mycophenolate and cyclosporine combination therapy in a renal transplant recipient Source: Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach Year: 2012
Methotrexate vs azathioprine in chronic sarcoidosis Source: Annual Congress 2012 - Sarcoidosis Year: 2012
Case series reporting the effectiveness of mycophenolate mofetil in treatment-resistant asthma Source: Eur Respir J 2013; 42: 1134-1137 Year: 2013
Effect and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis. A retrospective study Source: Annual Congress 2011 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2011
Cyclophosphamide in steroid-refractory hypersensitivity pneumonitis and non-classifiable interstitial lung disease Source: International Congress 2017 – Novel and old entities Year: 2017
Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis Source: ERJ Open Res, 3 (3) 00016-2017; 10.1183/23120541.00016-2017 Year: 2017
Comparison of post renal transplant tuberculosis cases receiving conventional immunosupressive therapy and mycophenolat mofetil (MMF) and/or tacrolimus (TAC) Source: Eur Respir J 2003; 22: Suppl. 45, 157s Year: 2003